NBS powder effect on the mortality rate of patients with covid-19

Investigating the effect of Nutrition Bio-Shield (NBS) herbal powder on inflammatory laboratory parameters and its effect on the mortality rate of patients with covid-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20230116057135N2

Enrollment

400

Registered

2023-04-05

Start date

2023-04-04

Completion date

Unknown

Last updated

2023-05-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Covid-19. COVID-19, virus identified

Interventions

Intervention 1: Intervention group: Patients in the intervention group, in addition to the standard treatment panel, receive Nutrition Bio-Shield (NBS) powder as follows: the amount of NBS 500 mg caps

Eligibility

Sex/Gender

All

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Patients over 20 years old Corona patients based on clinical symptoms, Computerized Tomography (CT) scan and laboratory tests such as Complete Blood Count (CBC), Erythrocyte Sedimentation Rate (ESR), C-Reactive Protein (CRP), Creatine Phosphokinase (CPK), Lactate Dehydrogenase (LDH), D-Dimer and finally Polymerase Chain Reaction (PCR) confirmation test for the presence of the infectious agent.

Exclusion criteria

Exclusion criteria: The patient's withdrawal from the study Patients with any other chronic disease such as diabetes, cardiovascular disease, etc. Patients who have received supplements of vitamin D, zinc, B vitamins and other micronutrients in the last month. Pregnant and lactating mothers Use of corticosteroids and immunosuppressive drugs Observing any drug sensitivity (especially digestive sensitivity to gluten) as determined by the attending physician Deterioration of the patient's clinical symptoms due to the consumption of NBS powder, as determined by the attending physician Patient's death during common and selective treatments (in case of death, the patient's information is fully recorded and laboratory tests are performed along with other samples to determine the possible effect of the drug on the patient's death)

Design outcomes

Primary

Measure	Time frame
Measurement of inflammatory factors. Timepoint: Before the start of the intervention, after the completion of the intervention. Method of measurement: Gold standard methods (ESR test by Westergren method, CRP test by Electrochemical Immunoassay method, D-Dimer test by latex rapid kit method).;Measurement of white blood cells. Timepoint: Before the start of the intervention, after the completion of the intervention. Method of measurement: Cell Counter.	—

Measure

Time frame

Measurement of inflammatory factors. Timepoint: Before the start of the intervention, after the completion of the intervention. Method of measurement: Gold standard methods (ESR test by Westergren method, CRP test by Electrochemical Immunoassay method, D-Dimer test by latex rapid kit method).;Measurement of white blood cells. Timepoint: Before the start of the intervention, after the completion of the intervention. Method of measurement: Cell Counter.

—

Secondary

Measure	Time frame
Mortality Rate. Timepoint: After the completion of the intervention. Method of measurement: Checking the patient's vital signs.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMehrdad Mosadegh

Tehran University of Medical Sciences

m-mosadegh@razi.tums.ac.ir+98 935 563 3390

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026